8YY Stock Overview
Biolidics Limited, a precision medicine medical technology company, focuses on developing a portfolio of diagnostic solutions.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Biolidics Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | S$0.012 |
52 Week High | S$0.022 |
52 Week Low | S$0.01 |
Beta | 0.71 |
1 Month Change | -7.69% |
3 Month Change | -7.69% |
1 Year Change | -20.00% |
3 Year Change | -95.71% |
5 Year Change | -96.07% |
Change since IPO | -94.89% |
Recent News & Updates
Recent updates
Shareholder Returns
8YY | SG Medical Equipment | SG Market | |
---|---|---|---|
7D | 0% | -3.5% | 1.9% |
1Y | -20.0% | -6.4% | -4.4% |
Return vs Industry: 8YY underperformed the SG Medical Equipment industry which returned -5.5% over the past year.
Return vs Market: 8YY underperformed the SG Market which returned -4.4% over the past year.
Price Volatility
8YY volatility | |
---|---|
8YY Average Weekly Movement | 13.0% |
Medical Equipment Industry Average Movement | 6.4% |
Market Average Movement | 4.8% |
10% most volatile stocks in SG Market | 14.1% |
10% least volatile stocks in SG Market | 2.2% |
Stable Share Price: 8YY's share price has been volatile over the past 3 months.
Volatility Over Time: 8YY's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of SG stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 30 | STY Song | https://www.biolidics.com |
Biolidics Limited, a precision medicine medical technology company, focuses on developing a portfolio of diagnostic solutions. The company operates through Cancer, Infectious Diseases, and Laboratory Services segments. It provides Covid-19 PCR testing kits.
Biolidics Limited Fundamentals Summary
8YY fundamental statistics | |
---|---|
Market cap | S$8.94m |
Earnings (TTM) | -S$2.49m |
Revenue (TTM) | S$1.36m |
6.6x
P/S Ratio-3.6x
P/E RatioIs 8YY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
8YY income statement (TTM) | |
---|---|
Revenue | S$1.36m |
Cost of Revenue | S$749.00k |
Gross Profit | S$612.00k |
Other Expenses | S$3.10m |
Earnings | -S$2.49m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0033 |
Gross Margin | 44.97% |
Net Profit Margin | -182.81% |
Debt/Equity Ratio | -85.1% |
How did 8YY perform over the long term?
See historical performance and comparison